all report title image
  • Published On : Jul 2022
  • Code : CMI4161
  • Industry : Pharmaceutical
  • Pages : 207
  • Formats :
Ingographics Image

Achondroplasia is a form of short-limbed dwarfism. Achondroplasia is characterized by an average-sized trunk, short arms and legs, notably short upper arms and thighs, limited range of motion at the elbows, and an enlarged head. Spinal stenosis, a narrowing of the spinal canal that can compress the upper section of the spinal cord, is a potentially serious complication of achondroplasia. Spinal stenosis is characterized by leg pain, tingling, and weakness, which can make walking difficult. Achondroplasia is caused by mutations in the FGFR3 gene. The FGFR3 gene is responsible for giving instructions during making a protein that is involved in the development and maintenance of bone and brain tissue.

Market Dynamics

The increasing approvals from the regulatory bodies to the key players in the market for the achondroplasia treatment drugs are expected to drive the market growth over the forecast period. For instance, in November 2021, BioMarin, a global biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval to VOXZOGO (vosoritide) for injection, indicated to increase linear growth in pediatric patients with achondroplasia of five years of age and older with open epiphyses (growth plates).

Moreover, in August 2021, QED Therapeutics, a subsidiary of BridgeBio Pharma, Inc., announced that the European Commission (EC) had granted marketing authorization for VOXZOGO (vosoritide), a once daily injection to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height.

Key features of the study:

  • This report provides an in-depth analysis of the global achondroplasia market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global achondroplasia market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include BioMarin, RIBOMIC, Ascendis Pharma A/S, BridgeBio Pharma, Inc., Pfizer Inc., PhaseBio Pharmaceuticals, Inc., SiSaf, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, LG Chem, Ferring B.V., JCR Pharmaceuticals Co., Ltd, KVK TECH, INC., VIVUS LLC., ProLynx Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Ipsen Pharma, Novartis AG, and Xiamen Amoytop Biotech Co., Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global achondroplasia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global achondroplasia market

Detailed Segmentation:

  • Global Achondroplasia Market, By Treatment Type:
    • Vosoritide
    • Human Growth Hormone 
    • Others
  • Global Achondroplasia Market, By Route of Administration:
    • Oral
    • Parenteral
  • Global Achondroplasia Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies 
    • Online Pharmacies  
  • Global Achondroplasia Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • BioMarin
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • RIBOMIC
    • Ascendis Pharma A/S
    • BridgeBio Pharma, Inc.
    • Pfizer Inc.
    • PhaseBio Pharmaceuticals, Inc.
    • SiSaf
    • Novo Nordisk A/S
    • Hoffmann-La Roche Ltd
    • LG Chem
    • Ferring B.V.
    • JCR Pharmaceuticals Co., Ltd
    • KVK TECH, INC.
    • VIVUS LLC.
    • ProLynx Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lilly and Company
    • Ipsen Pharma
    • Novartis AG
    • Xiamen Amoytop Biotech Co., Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Treatment Type
      • Market Snapshot, By Route of Administration
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Treatment Approaches for Achondroplasia
    • Merger, Acquisition & Agreements
    • Pipeline Analysis
    • Regulatory Scenario
    • PEST Analysis
    • Epidemiology
    • Therapeutics Overview
  4. Global Achondroplasia Market- Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • COVID-19 Epidemiology
    • Research and Development
  5. Global Achondroplasia Market, By Treatment Type, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Vosoritide
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Human Growth Hormone 
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Others
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  6. Global Achondroplasia Market, By Route of Administration, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Oral
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Parenteral
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  7. Global Achondroplasia Market, By Distribution Channel, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Hospital Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Retail Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Online Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  8. Global Achondroplasia Market, By Region, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 – 2030
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • UK
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
  9. Competitive Landscape
    • BioMarin
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • RIBOMIC    
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Ascendis Pharma A/S 
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • BridgeBio Pharma, Inc. 
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Pfizer Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • PhaseBio Pharmaceuticals, Inc. 
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • SiSaf 
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Novo Nordisk A/S 
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • F. Hoffmann-La Roche Ltd 
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • LG Chem
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Ferring B.V. 
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • JCR Pharmaceuticals Co., Ltd 
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • KVK TECH, INC.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • VIVUS LLC.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • ProLynx Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Eli Lilly and Company
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Ipsen Pharma
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Novartis AG
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Xiamen Amoytop Biotech Co., Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
  10. Section
    • Research Methodology
    • About Us

*Browse 35 market data tables and 29 figures on "Global Achondroplasia Market” - forecast to 2030

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo